{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:52:02Z","timestamp":1784742722317,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10689-025-00448-w","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:41:45Z","timestamp":1739925705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CHEK2-related breast cancer: real-world challenges"],"prefix":"10.1007","volume":"24","author":[{"given":"Luiza N.","family":"Weis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany L.","family":"Bychkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela Rodr\u00edguez","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata L.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"448_CR1","unstructured":"NCCN Clinical practice guidelines in oncology. genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Version 3.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Accessed on: March 27, 2024."},{"key":"448_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI et al (2024) Germline testing in patients with breast cancer: ASCO-society of surgical oncology guideline. J Clin Oncol 42:584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225","journal-title":"J Clin Oncol"},{"key":"448_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Breast Cancer Association Consortium, Dorling L, Carvalho S et al (2021) Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med 384:428\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1913948","journal-title":"N Engl J Med"},{"key":"448_CR4","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2001","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389\u20131399. https:\/\/doi.org\/10.1016\/S0140-6736(01)06524-2","journal-title":"Lancet"},{"key":"448_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384:440\u2013451. https:\/\/doi.org\/10.1056\/NEJMoa2005936","journal-title":"N Engl J Med"},{"key":"448_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55\u201359. https:\/\/doi.org\/10.1038\/ng879","journal-title":"Nat Genet"},{"key":"448_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2022.4071","volume":"8","author":"BL Bychkovsky","year":"2022","unstructured":"Bychkovsky BL, Agaoglu NB, Horton C et al (2022) Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2. JAMA Oncol 8:1598\u20131606. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4071","journal-title":"JAMA Oncol"},{"key":"448_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00484","author":"S Gallagher","year":"2021","unstructured":"Gallagher S, Hughes E, Kurian AW et al (2021) Comprehensive breast cancer risk assessment for CHEK2 and ATM pathogenic variant carriers incorporating a polygenic risk score and the Tyrer-Cuzick model. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.20.00484","journal-title":"JCO Precis Oncol"},{"key":"448_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jnci\/djaa203","volume":"113","author":"J Borde","year":"2021","unstructured":"Borde J, Ernst C, Wappenschmidt B et al (2021) Performance of breast cancer polygenic risk scores in 760 female chek2 germline mutation carriers. J Natl Cancer Inst 113:893\u2013899. https:\/\/doi.org\/10.1093\/jnci\/djaa203","journal-title":"J Natl Cancer Inst"},{"key":"448_CR10","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","volume":"29","author":"C Cybulski","year":"2011","unstructured":"Cybulski C, Wokolorczyk D, Jakubowska A et al (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29:3747\u20133752. https:\/\/doi.org\/10.1200\/JCO.2010.34.0778","journal-title":"J Clin Oncol"},{"key":"448_CR11","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Boughey JC, Pierce LJ et al (2020) Management of hereditary breast cancer: american society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline. J Clin Oncol 38:2080\u20132106. https:\/\/doi.org\/10.1200\/JCO.20.00299","journal-title":"J Clin Oncol"},{"key":"448_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","volume":"8","author":"KP Lowry","year":"2022","unstructured":"Lowry KP, Geuzinge HA, Stout NK et al (2022) Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis. JAMA Oncol 8:587\u2013596. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6204","journal-title":"JAMA Oncol"},{"key":"448_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100870","volume":"25","author":"H Hanson","year":"2023","unstructured":"Hanson H, Astiazaran-Symonds E, Amendola LM et al (2023) Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the american college of medical genetics and genomics (ACMG). Genet Med 25:100870. https:\/\/doi.org\/10.1016\/j.gim.2023.100870","journal-title":"Genet Med"},{"key":"448_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1200\/JCO.22.01239","volume":"41","author":"S Yadav","year":"2023","unstructured":"Yadav S, Boddicker NJ, Na J et al (2023) Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol 41:1703\u20131713. https:\/\/doi.org\/10.1200\/JCO.22.01239","journal-title":"J Clin Oncol"},{"key":"448_CR15","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","volume":"286","author":"DW Bell","year":"1999","unstructured":"Bell DW, Varley JM, Szydlo TE et al (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528\u20132531. https:\/\/doi.org\/10.1126\/science.286.5449.2528","journal-title":"Science"},{"key":"448_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6744","volume":"8","author":"N Mavaddat","year":"2022","unstructured":"Breast Cancer Association Consortium, Mavaddat N, Dorling L et al (2022) Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol 8:e216744. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6744","journal-title":"JAMA Oncol"},{"key":"448_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaoncol.2023.6287","volume":"10","author":"J Rodriguez","year":"2024","unstructured":"Rodriguez J, Grassmann F, Xiao Q et al (2024) Investigation of genetic alterations associated with interval breast cancer. JAMA Oncol 10:372\u2013379. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6287","journal-title":"JAMA Oncol"},{"key":"448_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","volume":"14","author":"L Dorling","year":"2022","unstructured":"Dorling L, Carvalho S, Allen J et al (2022) Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med 14:51. https:\/\/doi.org\/10.1186\/s13073-022-01052-8","journal-title":"Genome Med"},{"key":"448_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","volume":"53","author":"MC Southey","year":"2016","unstructured":"Southey MC, Goldgar DE, Winqvist R et al (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53:800\u2013811. https:\/\/doi.org\/10.1136\/jmedgenet-2016-103839","journal-title":"J Med Genet"},{"key":"448_CR20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1086\/421251","volume":"74","author":"CHEK2 Breast Cancer Case-Control Consortium","year":"2004","unstructured":"CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175\u20131182. https:\/\/doi.org\/10.1086\/421251","journal-title":"Am J Hum Genet"},{"key":"448_CR21","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1038\/s41598-022-07383-1","volume":"12","author":"RSC Guindalini","year":"2022","unstructured":"Guindalini RSC, Viana DV, Kitajima J et al (2022) Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep 12:4190. https:\/\/doi.org\/10.1038\/s41598-022-07383-1","journal-title":"Sci Rep"},{"key":"448_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070881","author":"D Garmendia","year":"2024","unstructured":"Garmendia D, Weidner A, Venton L, Pal T (2024) Comparing cancer risk management between females with truncating CHEK2 1100delC versus missense CHEK2 I157T variants. Genes (Basel). https:\/\/doi.org\/10.3390\/genes15070881","journal-title":"Genes (Basel)"},{"key":"448_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L et al (2021) Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 7:230\u2013237. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6252","journal-title":"JAMA Oncol"},{"key":"448_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41698-023-00429-1","volume":"7","author":"N Tung","year":"2023","unstructured":"Tung N, Dougherty KC, Gatof ES et al (2023) Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing. NPJ Precis Oncol 7:76. https:\/\/doi.org\/10.1038\/s41698-023-00429-1","journal-title":"NPJ Precis Oncol"},{"key":"448_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JOP.19.00201","volume":"15","author":"K DeLeonardis","year":"2019","unstructured":"DeLeonardis K, Hogan L, Cannistra SA, Rangachari D, Tung N (2019) When should tumor genomic profiling prompt consideration of germline testing? J Oncol Pract 15:465\u2013473. https:\/\/doi.org\/10.1200\/JOP.19.00201","journal-title":"J Oncol Pract"},{"key":"448_CR26","unstructured":"ClinVar - NCBI. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/128071\/. Accessed 27 Jul 2024."},{"key":"448_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113254","author":"A Brandao","year":"2020","unstructured":"Brandao A, Paulo P, Maia S et al (2020) The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12113254","journal-title":"Cancers (Basel)"},{"key":"448_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cancergen.2023.10.002","volume":"278\u2013279","author":"E Mundt","year":"2023","unstructured":"Mundt E, Mabey B, Rainville I et al (2023) Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: a comparison of missense versus truncating variants. Cancer Genet 278\u2013279:84\u201390. https:\/\/doi.org\/10.1016\/j.cancergen.2023.10.002","journal-title":"Cancer Genet"},{"key":"448_CR29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","volume":"26","author":"M Weischer","year":"2008","unstructured":"Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26:542\u2013548. https:\/\/doi.org\/10.1200\/JCO.2007.12.5922","journal-title":"J Clin Oncol"},{"key":"448_CR30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","volume":"34","author":"C Naslund-Koch","year":"2016","unstructured":"Naslund-Koch C, Nordestgaard BG, Bojesen SE (2016) Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the copenhagen general population study. J Clin Oncol 34:1208\u20131216. https:\/\/doi.org\/10.1200\/JCO.2015.63.3594","journal-title":"J Clin Oncol"},{"key":"448_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/thy.2023.0529","volume":"34","author":"P Brock","year":"2024","unstructured":"Brock P, Liynarachchi S, Nieminen TT et al (2024) CHEK2 founder variants and thyroid cancer risk. Thyroid 34:477\u2013483. https:\/\/doi.org\/10.1089\/thy.2023.0529","journal-title":"Thyroid"},{"key":"448_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10549-015-3628-4","volume":"154","author":"A Macacu","year":"2015","unstructured":"Macacu A, Autier P, Boniol M, Boyle P (2015) Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat 154:213\u2013224. https:\/\/doi.org\/10.1007\/s10549-015-3628-4","journal-title":"Breast Cancer Res Treat"},{"key":"448_CR33","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/ijc.31257","volume":"142","author":"KP Ko","year":"2018","unstructured":"Ko KP, Kim SJ, Huzarski T et al (2018) The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. Int J Cancer 142:2263\u20132272. https:\/\/doi.org\/10.1002\/ijc.31257","journal-title":"Int J Cancer"},{"key":"448_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.18632\/oncotarget.28604","volume":"15","author":"AR Hernandez","year":"2024","unstructured":"Hernandez AR, Scheib R, Garber JE, Rana HQ, Bychkovsky BL (2024) Genotype matters: personalized screening recommendations for germline CHEK2 variants. Oncotarget 15:459\u2013460. https:\/\/doi.org\/10.18632\/oncotarget.28604","journal-title":"Oncotarget"},{"key":"448_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/gim.2016.147","volume":"19","author":"TA Muranen","year":"2017","unstructured":"Muranen TA, Greco D, Blomqvist C et al (2017) Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genet Med 19:599\u2013603. https:\/\/doi.org\/10.1038\/gim.2016.147","journal-title":"Genet Med"},{"key":"448_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf2860","author":"E Oropeza","year":"2023","unstructured":"Oropeza E, Seker S, Carrel S et al (2023) Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.adf2860","journal-title":"Sci Adv"},{"key":"448_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.radonc.2006.12.002","volume":"82","author":"A Meyer","year":"2007","unstructured":"Meyer A, Dork T, Sohn C, Karstens JH, Bremer M (2007) Breast cancer in patients carrying a germ-line CHEK2 mutation: outcome after breast conserving surgery and adjuvant radiotherapy. Radiother Oncol 82:349\u2013353. https:\/\/doi.org\/10.1016\/j.radonc.2006.12.002","journal-title":"Radiother Oncol"},{"key":"448_CR38","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","volume":"34","author":"MK Schmidt","year":"2016","unstructured":"Schmidt MK, Hogervorst F, van Hien R et al (2016) Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol 34:2750\u20132760. https:\/\/doi.org\/10.1200\/JCO.2016.66.5844","journal-title":"J Clin Oncol"},{"key":"448_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00178","author":"SL Greville-Heygate","year":"2020","unstructured":"Greville-Heygate SL, Maishman T, Tapper WJ et al (2020) Pathogenic variants in CHEK2 are associated with an adverse prognosis in symptomatic early-onset breast cancer. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.19.00178","journal-title":"JCO Precis Oncol"},{"key":"448_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12885-015-1203-3","volume":"15","author":"Y Liu","year":"2015","unstructured":"Liu Y, Xu Y, Ouyang T et al (2015) Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer. BMC Cancer 15:194. https:\/\/doi.org\/10.1186\/s12885-015-1203-3","journal-title":"BMC Cancer"},{"key":"448_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10549-023-07176-8","volume":"204","author":"CJ Schwartz","year":"2024","unstructured":"Schwartz CJ, Khorsandi N, Blanco A, Mukhtar RA, Chen YY, Krings G (2024) Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants. Breast Cancer Res Treat 204:171\u2013179. https:\/\/doi.org\/10.1007\/s10549-023-07176-8","journal-title":"Breast Cancer Res Treat"},{"key":"448_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1399-0004.2008.01111.x","volume":"75","author":"C Cybulski","year":"2009","unstructured":"Cybulski C, Huzarski T, Byrski T et al (2009) Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet 75:72\u201378. https:\/\/doi.org\/10.1111\/j.1399-0004.2008.01111.x","journal-title":"Clin Genet"},{"key":"448_CR43","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97:1652\u20131662. https:\/\/doi.org\/10.1093\/jnci\/dji372","journal-title":"J Natl Cancer Inst"},{"key":"448_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF et al (2020) Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395:117\u2013122. https:\/\/doi.org\/10.1016\/S0140-6736(19)32955-1","journal-title":"Lancet"},{"key":"448_CR45","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel VG, Costantino JP, Wickerham DL et al (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 3:696\u2013706. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0076","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00448-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T18:41:23Z","timestamp":1745260883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00448-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00448-w","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LNW has received honoraria from Libbs, Novartis and Roche and travel accommodations or expenses from Libbs, GSK and Daiichi-Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Research Ethical Committee of the Hospital S\u00edrio-Liban\u00eas (CAAE 21735619.3.0000.5461) and a waiver of informed consent was granted. All clinical and molecular data were de-identified before data sharing and analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"23"}}